Tvardi Therapeutics
TVRD
43 hedge funds and large institutions have $6.59M invested in Tvardi Therapeutics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 18 reducing their positions, and 32 closing their positions.
58% more capital invested
Capital invested by funds: $4.17M → $6.59M (+$2.42M)
0.02% less ownership
Funds ownership: 0.69% → 0.67% (-0.02%)
38% less funds holding
Funds holding: 69 → 43 (-26)
50% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 18
78% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 32
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rockefeller Capital Management
New York
|
+$565K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$389K |
| 3 |
SC
Shay Capital
New York
|
+$311K |
| 4 |
CRC
Curi RMB Capital
Chicago,
Illinois
|
+$164K |
| 5 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
+$67.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
C
Chescapmanager
Baltimore,
Maryland
|
-$524K |
| 2 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
-$343K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$128K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$103K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$97.4K |
TVRD Hedge Fund Activity: Q4 2024 in Review
43 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2024, worth a combined $6.59M — up 58% from $4.17M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of TVRD and 7 opened new positions — a net loss of 25 holders — while 18 trimmed existing stakes and 9 added.
The largest buyer was Rockefeller Capital Management, opening a new position worth an estimated $565K. The largest seller was Chescapmanager, exiting entirely with an estimated $524K sold.
- 43 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2024, down from 69 in Q3 2024.
- Funds reported $6.59M of Tvardi Therapeutics stock for Q4 2024, up 58% quarter-over-quarter.
- 7 funds opened new Tvardi Therapeutics positions in Q4 2024 and 32 closed out, a net change of -25 holders.
- The largest Tvardi Therapeutics buyer in Q4 2024 was Rockefeller Capital Management, an estimated $565K added.
- The largest Tvardi Therapeutics seller in Q4 2024 was Chescapmanager, an estimated $524K sold.
Based on aggregated 13F filings for Q4 2024.